These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26231040)

  • 1. Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Evans B; Griner E;
    Elife; 2015 Jul; 4():e07420. PubMed ID: 26231040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Fiehn O; Showalter MR; Schaner-Tooley CE; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26943899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Richarson AD; Scott DA; Zagnitko O; Aza-Blanc P; Chang CC; Russler-Germain DA;
    Elife; 2016 Mar; 5():e10860. PubMed ID: 26971564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
    Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
    Elife; 2017 Jun; 6():. PubMed ID: 28653623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.
    Phelps M; Coss C; Wang H; Cook M; ;
    Elife; 2016 Mar; 5():. PubMed ID: 26943900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
    Wang P; Wu J; Ma S; Zhang L; Yao J; Hoadley KA; Wilkerson MD; Perou CM; Guan KL; Ye D; Xiong Y
    Cell Rep; 2015 Dec; 13(11):2353-2361. PubMed ID: 26686626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-2-Hydroxyglutarate in Glioma Biology.
    Chou FJ; Liu Y; Lang F; Yang C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Sharma V; Young L; Cavadas M; Owen K;
    Elife; 2016 Mar; 5():. PubMed ID: 26999821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.
    Khan I; Kerwin J; Owen K; Griner E; ;
    Elife; 2015 Sep; 4():. PubMed ID: 26335297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers.
    Sharma V; Young L; Allison AB; Owen K; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26894955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia.
    Fung JJ; Kosaka A; Shan X; Danet-Desnoyers G; Gormally M; Owen K; ;
    Elife; 2015 Sep; 4():. PubMed ID: 26327698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registered report: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.
    Fiering S; Ang LH; Lacoste J; Smith TD; Griner E;
    Elife; 2015 Jul; 4():e04796. PubMed ID: 26179155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
    Haven B; Heilig E; Donham C; Settles M; Vasilevsky N; Owen K; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26905833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.
    Peng S; Chen H; Chen L; Yang G; Liu J; Cheng X; Tang Y
    Chem Res Toxicol; 2022 Feb; 35(2):115-124. PubMed ID: 35018778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
    Vanden Heuvel JP; Bullenkamp J;
    Elife; 2016 Jun; 5():. PubMed ID: 27336789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Bhargava A; Pelech S; Woodard B; Kerwin J; Maherali N; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26882073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Registered report: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
    Lesnik J; Antes T; Kim J; Griner E; Pedro L; ;
    Elife; 2016 Jan; 5():e07383. PubMed ID: 26826285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registered report: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.
    Evans J; Essex A; Xin H; Amitai N; Brinton L; Griner E; ;
    Elife; 2015 Aug; 4():. PubMed ID: 26287525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.